Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  MANAGEMENT DISCUSSION
Management Discussion      
Belding India Ltd.
BSE Code 513307
ISIN Demat INE363L01045
Book Value 728.56
NSE Code NA
Dividend Yield % 0.00
Market Cap 25304.68
P/E 1455.13
EPS 1.20
Face Value 10  
Year End: March 2014
 

Management Discussion and Analysis Report

A. Industry structure and development:

India has witnessed a huge transformation in economic and social growth resulting into emergence of the large Aluminium Foil Industry. This industry brdominantly is run by large companies as well as small scale operations by individual operators but has been transformed into organized structured Industry recognized as Packaging products mainly in Food sector Pharmaceutical, Caterings, Railways, Airlines, Hotels, Restaurants, etc. Aluminium being protective layer from moisture, light etc and biodegradable is good for Pharma packaging. Further the product application for Aluminium foils has been into Health and Hygiene sector also like Hospitals and Health centres resulting into a sector being termed as Aluminium Consumer goods sector. The Country has been seeing huge demand of this products due to increased urbanization and increase exports of Pharmaceuticals resulting into growth by existing players and also few global Companies are trying to market their product initially and may get into operations as and when they find the market ready for their products. Further the Company is constantly looking to expand to newer markets; thereby increasing the overall market of the products.

Opportunities and strengths

The young population, urbanization, international exposure to the current people, environmental rules and regulations, nuclear family concepts, huge demand for improved hygiene levels, huge growth in direct customer markets, provides huge opportunities to scale up this business and industry will see huge multiple growth in years to come.

Outlook, risks and concerns

The current plants of the Company are at two locations. Due to that Company derives huge economies of scale & efficiencies. But there is always a risk of any natural / unnatural eventualities occurring; that shall effect the partial operations of the Company. Since Company is entering direct sales; there would be challenges over supply chain, logistics etc. Inventories and debtors level is expected to be high till such time that the direct business stabilizes. Demand not matching up with the supply as by the end of 2013-14 production capacities of the Company would be almost at the optimum utilization. There could be a slight drop in the bottomline in case of finance cost going up.

CURRENT YEAR'S OUTLOOK

Going forward Company plans to focus more towards direct customer business, product brand building, develop custom made products for Pharmaceutical Industries. This will result in a fundamental change in perception about the Company and there will be lots of value addition thereby increasing the bottom line of the Company. Branding of the Company's product range will also improve the image of the Company. Company is also in process of putting various systems/ processes in place, so that eventually the Company is system/ processes driven. We are also in the process of building a much stronger and professional team in various faculties to facilitate smooth working.

Based on Company's order book position and execution capabilities; we are hopeful of achieving 15% growth in the topline of the Company. We also expect to increase our direct business share, to launch the new pharmaceutical packaging. We target to have everything in place by this yearend so as to kick start the business from early next year onwards. In the current year we shall also be exploring new markets for exports. Overall we look to the immediate future with optimism & sense of wellbeing.

Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.